The Current Landscape of PARP Inhibitors in Ovarian Cancer

The Current Landscape of PARP Inhibitors in Ovarian Cancer Purpose of Review The aim of this study is to discuss the background of PARP inhibitors and to provide an overview of the utility of these drugs for treatment of epithelial ovarian cancer. Recent Findings Numerous phase I–III trials are presented within the manuscript that outline the safety and efficacy of several PARP inhibitors in women with primary and recurrent ovarian cancer. There are now three FDA-approved PARP inhibitors for use in ovarian cancer patients in the USA: olaparib, niraparib, and rucaparib. These drugs have activity both alone and in combination with other agents, including chemotherapy and targeted anti-cancer drugs. Although PARP inhibitor toxicities often overlap with chemotherapy including myelosuppression, fatigue, and gastrointestinal distress, there are idiosyncratic differences in adverse event profiles and peculiar aspects of each drug. Additionally, the indications for use differ with respect to line of chemotherapy, whether a germline or somatic BRCA mutation is required, and maintenance versus active treatment intention. Although these were initially thought to be only applicable to patients with germline BRCA mutations, we now know that other patients benefit from these agents alone and in combination. Summary The first PARP inhibitor was approved for use in the USA less than 3 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Obstetrics and Gynecology Reports Springer Journals

The Current Landscape of PARP Inhibitors in Ovarian Cancer

Loading next page...
 
/lp/springer_journal/the-current-landscape-of-parp-inhibitors-in-ovarian-cancer-xKdCMovz8g
Publisher
Springer US
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Obstetrics/Perinatology/Midwifery; Maternal and Child Health; Medicine/Public Health, general; Oncology
eISSN
2161-3303
D.O.I.
10.1007/s13669-018-0233-7
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review The aim of this study is to discuss the background of PARP inhibitors and to provide an overview of the utility of these drugs for treatment of epithelial ovarian cancer. Recent Findings Numerous phase I–III trials are presented within the manuscript that outline the safety and efficacy of several PARP inhibitors in women with primary and recurrent ovarian cancer. There are now three FDA-approved PARP inhibitors for use in ovarian cancer patients in the USA: olaparib, niraparib, and rucaparib. These drugs have activity both alone and in combination with other agents, including chemotherapy and targeted anti-cancer drugs. Although PARP inhibitor toxicities often overlap with chemotherapy including myelosuppression, fatigue, and gastrointestinal distress, there are idiosyncratic differences in adverse event profiles and peculiar aspects of each drug. Additionally, the indications for use differ with respect to line of chemotherapy, whether a germline or somatic BRCA mutation is required, and maintenance versus active treatment intention. Although these were initially thought to be only applicable to patients with germline BRCA mutations, we now know that other patients benefit from these agents alone and in combination. Summary The first PARP inhibitor was approved for use in the USA less than 3

Journal

Current Obstetrics and Gynecology ReportsSpringer Journals

Published: Mar 3, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off